• Aluminium pouches with a Microwell Plate coated with monoclonal antibody to human GDF-15 (8x12)
• 2 vials human GDF-15 Standard lyophilized, 1000 pg/ml upon reconstitution
• 2 vials concentrated Biotin-Conjugate anti-human GDF-15 monoclonal antibody
• 2 vials Streptavidin-HRP solution
• 1 bottle Standard /sample Diluent
• 1 bottle Biotin-Conjugate antibody Diluent
• 1 bottle Streptavidin-HRP Diluent
• 1 bottle Wash Buffer Concentrate 20x (PBS with 1% Tween-20)
• 1 vial Substrate Solution
• 1 vial Stop Solution
• 3 pieces Adhesive Films
• package insert

Growth and differentiation factor-15 (GDF-15), also known as macrophage inhibitory cytokine-1(MIC-1), placental transforming growth factor-β, prostate-derived factor, and placental bone morphogenetic protein, is a divergent member of the transforming growth factor beta (TGF-β) superfamily (1 - 3). GDF-15 is initially synthesized as a 40 kDa inactive precursor protein. It is then proteolytically cleaved to release the active C-terminal fragment, which is assembled into a disulfide-linked homodimer of 28 kDa to become biologically active GDF-15 (1, 4). In humans, GDF-15 is predominantly expressed in the placenta, with low levels in the kidney, pancreas, and prostate. However, its expression can be rapidly induced by cytokines such as interleukin-1 and TGF-β (1 - 3).

GDF-15 has diverse biological functions. Early studies have shown that low serum GDF-15 levels correlate with miscarriages, indicating that it might be able to suppress inflammation in early pregnancy (5, 6). GDF-15 also plays an important role in tumorigenesis and metastasis. It has been observed that in many types of cancers, such as colorectal, breast, and prostate, the expression of GDF-15 is dramatically increased (7 - 9). Additionally, in cancer patients, serum levels of GDF-15 are elevated, which are of value in disease diagnosis and stratification (10 -12). GDF-15 is strongly induced by the tumor suppressor gene p53 and other anti-tumorigenic agents, such as the non-steroidal anti-inflammatory drugs and peroxisome proliferators-activated receptor γ. These findings suggest that GDF-15 may be a downstream target of those signaling pathways that regulate cell cycle arrest and apoptosis (13 - 15). Through the modulation of neuronal pathways important in the regulation of appetite and energy homeostasis, GDF-15 mediates cancer-induced anorexia and weight loss (16).

Bootcov, M.R. et al. (1997) Proc. Natl. Acad. Sci. USA 94:11514.

Lawton, L.N. et al. (1997) Gene 203:17.

Paralkar, V.M. et al. (1998) J. Biol. Chem. 273:13760.

Bauskin, A.R. et al. (2000) EMBO J. 19:2212.

Moore, A.G. et al. (2000) J. Clin. Endocrinol. Metab. 85:4781.

Tong, S. et al. (2004) Lancet 363:129.

Buckhaults, P. et al. (2001) Cancer Res. 61:6996.

Welsh, J.B. et al. (2003) Proc. Natl. Acad. Sci. USA 100:3410.

Cheung, P.K. et al. (2004) Cancer Res. 64:5929.

Koopmann, J. et al. (2004) Clinical Cancer Res. 10:2386.

Koopmann, J. et al. (2006) Clinical Cancer Res. 12:442.

Brown, D.A. et al. (2006) Clinical Cancer Res. 12:89.

Tan, M. et al. (2000) Proc. Natl. Acad. Sci. USA 97:109.

Li, P.X. et al. (2000) J. Biol. Chem. 75:20127.

Agarwal, M.K. et al. (2006) Proc. Natl. Acad. Sci. USA 103:16278.

Johnen, H. et al. (2007) Nat. Med. 13:1333.